FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018691301> ?p ?o ?g. }

• W2018691301 endingPage "61" @default.
• W2018691301 startingPage "51" @default.
• W2018691301 abstract "Availability of lipid formulations of amphotericin B has opened up the possibility of treating invasive fungal infections in immunocompromised patients with high doses of this antifungal agent. Evidence is emerging to suggest that lipid formulations may have heightened efficacy compared to conventional amphotericin B. The issue of optimal dosage has been a neglected area. This article reviews published data accrued from clinical, open-label, salvage, and other studies, and finds little support that the use of high doses of lipid formulations are more efficacious than lower doses. The response rates for invasive fungal infection from most studies are predictably around 56%, irrespective of the lipid formulation and dose used. Animal models provide evidence that low doses of a lipid formulation are as successful in reducing fungal dissemination and in prolonging survival as higher doses, although concomitant tissue fungal eradication is not as effectively achieved by the lower doses (survival-mycologic eradication dissociation). Kinetic studies performed in the clinically relevant setting of critically ill patients give further support to the use of low doses, since levels of liposomal amphotericin B at all dosages between 1 and 4 mg/kg/day are similar and above maximum inhibitory concentrations for commonly encountered fungi. There has only been one prospective randomised study designed with the primary end-point of comparing two dosages of an amphotericin B lipid formulation on clinical response and survival. That European Organization for Research and Treatment of Cancer (EORTC) study concluded that liposomal amphotericin B given at 1 mg was as efficacious as 4 mg/kg/day in treating neutropenic patients with invasive pulmonary aspergillosis. There are a multitude of unanswered questions concerning dosing, and their answers are confounded by difficulties in performing clinical trials and the multiplicity of factors other than antifungal chemotherapy that influence outcome. Maximum tolerated dose studies using existing lipid formulations, or perhaps with the newer formulations such as pegylated immunoliposomal amphotericin B, could be performed to shed light on this difficult area." @default.
• W2018691301 created "2016-06-24" @default.
• W2018691301 creator A5039035175 @default.
• W2018691301 date "2000-06-01" @default.
• W2018691301 modified "2023-10-18" @default.
• W2018691301 title "Amphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections?" @default.
• W2018691301 cites W130647520 @default.
• W2018691301 cites W1548386262 @default.
• W2018691301 cites W1908952024 @default.
• W2018691301 cites W1978263354 @default.
• W2018691301 cites W1979180336 @default.
• W2018691301 cites W1986277469 @default.
• W2018691301 cites W1986330094 @default.
• W2018691301 cites W1998840608 @default.
• W2018691301 cites W2004614326 @default.
• W2018691301 cites W2007960806 @default.
• W2018691301 cites W2014907435 @default.
• W2018691301 cites W2020136924 @default.
• W2018691301 cites W2034518597 @default.
• W2018691301 cites W2037064781 @default.
• W2018691301 cites W2044007911 @default.
• W2018691301 cites W2052042120 @default.
• W2018691301 cites W2053261047 @default.
• W2018691301 cites W2053542115 @default.
• W2018691301 cites W2058801629 @default.
• W2018691301 cites W2063287049 @default.
• W2018691301 cites W2066946030 @default.
• W2018691301 cites W2067682540 @default.
• W2018691301 cites W2076943906 @default.
• W2018691301 cites W2084450020 @default.
• W2018691301 cites W2084455533 @default.
• W2018691301 cites W2101504223 @default.
• W2018691301 cites W2109718032 @default.
• W2018691301 cites W2119390272 @default.
• W2018691301 cites W2120541149 @default.
• W2018691301 cites W2121087098 @default.
• W2018691301 cites W2126223328 @default.
• W2018691301 cites W2129423527 @default.
• W2018691301 cites W2129948097 @default.
• W2018691301 cites W2130882795 @default.
• W2018691301 cites W2135352158 @default.
• W2018691301 cites W2143660505 @default.
• W2018691301 cites W2144030592 @default.
• W2018691301 cites W2153548320 @default.
• W2018691301 cites W2154018274 @default.
• W2018691301 cites W2163206122 @default.
• W2018691301 cites W2169817597 @default.
• W2018691301 cites W2170019085 @default.
• W2018691301 cites W2233665167 @default.
• W2018691301 cites W2313278756 @default.
• W2018691301 cites W2326799365 @default.
• W2018691301 cites W2328084459 @default.
• W2018691301 cites W2329278381 @default.
• W2018691301 cites W38859737 @default.
• W2018691301 doi "https://doi.org/10.1034/j.1399-3062.2000.020203.x" @default.
• W2018691301 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11429013" @default.
• W2018691301 hasPublicationYear "2000" @default.
• W2018691301 type Work @default.
• W2018691301 sameAs 2018691301 @default.
• W2018691301 citedByCount "28" @default.
• W2018691301 countsByYear W20186913012018 @default.
• W2018691301 countsByYear W20186913012020 @default.
• W2018691301 countsByYear W20186913012023 @default.
• W2018691301 crossrefType "journal-article" @default.
• W2018691301 hasAuthorship W2018691301A5039035175 @default.
• W2018691301 hasConcept C126322002 @default.
• W2018691301 hasConcept C16005928 @default.
• W2018691301 hasConcept C162156334 @default.
• W2018691301 hasConcept C203092338 @default.
• W2018691301 hasConcept C2779384505 @default.
• W2018691301 hasConcept C2779548794 @default.
• W2018691301 hasConcept C2779629538 @default.
• W2018691301 hasConcept C535046627 @default.
• W2018691301 hasConcept C71924100 @default.
• W2018691301 hasConcept C98274493 @default.
• W2018691301 hasConceptScore W2018691301C126322002 @default.
• W2018691301 hasConceptScore W2018691301C16005928 @default.
• W2018691301 hasConceptScore W2018691301C162156334 @default.
• W2018691301 hasConceptScore W2018691301C203092338 @default.
• W2018691301 hasConceptScore W2018691301C2779384505 @default.
• W2018691301 hasConceptScore W2018691301C2779548794 @default.
• W2018691301 hasConceptScore W2018691301C2779629538 @default.
• W2018691301 hasConceptScore W2018691301C535046627 @default.
• W2018691301 hasConceptScore W2018691301C71924100 @default.
• W2018691301 hasConceptScore W2018691301C98274493 @default.
• W2018691301 hasIssue "2" @default.
• W2018691301 hasLocation W20186913011 @default.
• W2018691301 hasLocation W20186913012 @default.
• W2018691301 hasOpenAccess W2018691301 @default.
• W2018691301 hasPrimaryLocation W20186913011 @default.
• W2018691301 hasRelatedWork W1984309643 @default.
• W2018691301 hasRelatedWork W2002043275 @default.
• W2018691301 hasRelatedWork W2013703960 @default.
• W2018691301 hasRelatedWork W2045751973 @default.
• W2018691301 hasRelatedWork W2106653639 @default.
• W2018691301 hasRelatedWork W2583665135 @default.
• W2018691301 hasRelatedWork W3208389371 @default.
• W2018691301 hasRelatedWork W4221070417 @default.

• next